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Abstract
Background: Copy number variations (CNVs) of the gene CC chemokine ligand 3-like1 (CCL3L1) have been
implicated in HIV-1 susceptibility, but the association has been inconsistent. CCL3L1 shares homology with a cluster
of genes localized to chromosome 17q12, namely CCL3, CCL3L2, and, CCL3L3. These genes are involved in host
defense and inflammatory processes. Several CNV assays have been developed for the CCL3L1 gene.
Findings: Through pairwise and multiple alignments of these genes, we have shown that the homology between
these genes ranges from 50% to 99% in complete gene sequences and from 70-100% in the exonic regions, with
CCL3L1 and CCL3L3 being identical. By use of MEGA 4 and BioEdit, we aligned sense primers, anti-sense primers,
and probes used in several previously described assays against pre-multiple alignments of all four chemokine
genes. Each set of probes and primers aligned and matched with overlapping sequences in at least two of the
four genes, indicating that previously utilized RT-PCR based CNV assays are not specific for only CCL3L1. The four
available assays measured median copies of 2 and 3-4 in European and African American, respectively. The
concordance between the assays ranged from 0.44-0.83 suggesting individual discordant calls and inconsistencies
with the assays from the expected gene coverage from the known sequence.
Conclusions: This indicates that some of the inconsistencies in the association studies could be due to assays that
provide heterogenous results. Sequence information to determine CNV of the three genes separately would allow
to test whether their association with the pathogenesis of a human disease or phenotype is affected by an
individual gene or by a combination of these genes.
Background
A cluster of chemokines including the CCL3L-related
gene family have been localized on chromosome 17q12
[1]. By sequencing a BAC clone located in this segmen-
tal duplication region, Modi identified 2 complete copies
(CCL3L1 and CCL3L3) and one truncated copy
(CCL3L2)o ft h eCCL3 gene family [2]. It has been
reported that individuals with more copies of CCL3L1
than their population median are less susceptible to
HIV infection [3,4]. There seems to be a relationship
between the copy number of CCL3L1-containing seg-
mental duplications and viral load and HIV-specific
CD4+ and CD8+ T cell responses [5]. The copy number
of CCL3L1 influences risk of systemic lupus erythemato-
sis (SLE) and modifies the SLE-influencing effects
associated with the CCR5 genotype [6]; a higher copy
number (> 2) of CCL3L1 is a risk factor for rheumatoid
arthritis [7]. There is CCR5-CCL3L1 gene-gene interac-
tion in susceptibility to Kawasaki disease [8], and higher
numbers of infant CCL3L1 gene copies are associated
with reduced HIV transmission [9,10]. In theory, the
higher the copy number, the higher the ligand concen-
tration, which should protect from HIV infection or dis-
ease progression. Chimpanzees, with higher copies
(median of nine copy numbers), do not develop AIDS;
this suggests biological significance. Copy number varia-
tion (CNV) of CCL3L- genes also affects the rate of pro-
gression to AIDS in rhesus macaques [11]. Other
studies, however, do not show an association [12,13].
Although differences may exist in HIV progression out-
comes, treatment variations, or interactions with the co-
receptor CCR5 that result in differential associations,
the methods used to determine CNVs have not been
compared.
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requirement for relatively large amounts of high-quality
genomic DNA, and the inherent inaccuracies and high
costs of other quantification techniques, high-through-
put, real-time quantitative PCR (RT-PCR) assays have
been developed to determine copy numbers. These pro-
cedures are applicable for CCL3L1. Since this gene clus-
ter region is complex, some of the variations in the
findings relevant to associations could be due to the dif-
ferent primers and probes used for the RT-PCR assays.
To determine if this is the case, we evaluated different
assays used to measure gene copy numbers of CCL3L1.
Methods
We searched PubMed with the terms “MIP-1aPo r
MIP-1alpha P or LD78b or LD78beta or CCL3L1” for
articles published in English up to the end of Jan 2010,
and screened for publications specific to HIV/AIDS (and
also separately for other diseases) and involving use of
RT-PCR-based assays for examining copy numbers of
CCL3L1 gene. Sequences of primers and probes used in
RT-PCR assays in these publications were subjected to a
nucleotide blast search against the human genomic plus
transcript database on the National Center for Biotech-
nology Information (NCBI) website http://blast.ncbi.nlm.
nih.gov/Blast.cgi. The sequences of genes containing
these blast results were obtained from the UCSC Geno-
mic Browser and aligned to the human reference
sequence. Locations of exons, introns and untranslated
regions of these genes were annotated from the NCBI
Genome Browser. Pairwise, and multiple alignments
were performed on these gene sequences via ClustalW
in Molecular Evolutionary Genetics Analysis (MEGA 4)
[14] and in BioEdit [15]. Primers and probes were
aligned individually with each gene and then with all
pre-aligned genes in MEGA 4 and BioEdit.
We used four different assays from the current litera-
ture (CCL3L_PP1, CCL3L_PP2, CCL3L_PP3, and
CCL3L_PP4 in Table 1) in a previously described subset
of 47 European American and 48 African American
healthy controls [16] to quantify and examine the distri-
bution of the copy numbers and the concordance rates
between different assays in the two populations were
assessed. Briefly, we used the specific primer/probe
combinations (as shown in Table 1) to quantify the
copy numbers of CCL3L1 with the single-copy gene
hemoglobin, beta (HBB) serving as the internal control.
Real-time PCR was performed using an AB 7500 Fast
System (Applied Biosystems Inc.). Cycling conditions
were: 2 min at 50°C, 10 min at 95°C, and 40 cycles of
15 s at 92°C and 1 min at 60°C. Test genomic DNA
samples was diluted to obtain a concentration of 2.5 ng/
μl, and 2 ul (5 ng genomic DNA) was used in each reac-
tion. We ran each sample in triplicates across three 96-
well plates. We used the Applied Biosystems relative
quantification program to determine gene copy numbers
for the individual samples. The HBB gene that is present
at two copies per diploid genome was used to standar-
dize the gene copy number counts. Consistent with pre-
vious studies, we performed RT-PCR for each individual
in triplicate and determined the normalized relative
copy number by generating a standard curve and then
normalizing across samples by the results of the HBB
control gene and dividing the value obtained by the
reference individual. Rounding off the outcome from the
previous step to the nearest integer provided the esti-
mated copy number counts. The copy numbers match-
ing in triplicates and/or duplicates was used as the final
copy number for an individual sample.
Results
For the CCL3L1 gene, a Pubmed search generated 1059
articles, of which 218 were related to HIV/AIDS. Fifteen
of the 218 articles were studies relating to CCL3L1 copy
numbers; all involved RT-PCR-based assays. Primers
and probes used for the studies are summarized in
Table 1. Most of these RT-PCR assays were based on
the assay described by Towson et al. [17]; a few had
modifications. Four studies assessed association of
CCL3L1 copy numbers with other diseases (Kawasaki
disease, SLE, hepatitis C, and rheumatoid arthritis). All
of these association studies used RT-PCR assays that
were based on the CCL3L_PP1 primer-probe (described
in Table 1). Two studies involved use of RT-PCR-based
assays to examine mRNA expression of CCL3L1.
Q u e r yc o v e r a g eo fa b o v e7 0 %w i t h1 0 0 %m a x i m u m
identity from the nucleotide blast identified 4 genes,
namely CCL3 (geneID: 6348), CCL3L1 (geneID: 6349),
CCL3L2 (geneID: 390788), CCL3L3 (geneID: 414062),
CCL18 (geneID: 6362) and CCL24 (geneID: 6369). The
reference genomic sequences for CCL3 - (34415602 -
34417506), CCL3L1 - (34623842 - 34625730), CCL3L2 -
(34610211 - 34611454), CCL3L3 - (34522262 -
34524142) were mapped to human chromosome 17
sequence, accession # NC_000017.10 (Figure 1). Of
note, CCL18 (34391643 - 34398841) in chromosome 17
and CCL24 (75441114 - 75443033) also showed high
homology (> 50%) sequence. The annotations of exons,
introns and untranslated regions of these genes are
shown in Figure 1 (see additional file 1 for details).
Since CCL3L2 is considered a pseudo-gene, locations of
these regions were estimated based on the homology
this gene shares with CCL3, CCL3L1 and CCL3L3.A s
shown in Table 2, the homology in the complete gene
region of the four CCL3L related genes in chromosome
17q12 was high (55.3 - 98.7%) and even higher in the
exonic region (71.9-100%), with identical exonic
sequences between CCL3L1 and CCL3L3.
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(labeled CCL3L_PP1-CCL3L_PP7) for both RT-PCR and
mRNA expression-based assays showed varying align-
ments with these four genes (additional file 1), suggest-
ing non-specific amplifications and gene copy number
determination. As shown in Table 1, all RT-PCR based
assays were specific for both CCL3L1 and CCL3L3,
except CCL3L_PP3, which was specific for CCL3L1,
CCL3L2,a n dCCL3L3 and CCL3L_PP7 for mRNA
Table 1 Specificity of primer and probes sets used in different HIV/AIDS and other disease association studies of
CCL3L-related CNVs and mRNA expression.
# Primer/Probe Sequences
5’-3’ Sequence*
References Specificity
HIV/AIDS Other diseases
CCL3L_PP1 F: TCTCCACAGCTTCCTAACCAAGA [3,4], [6]
a CCL3L1
R: CTGGACCCACTCCTCACTGG [5,9], [7]
b CCL3L3
P: AGGCCGGCAGGTCTGTGCTGA [10,17], [8]
c
[22,23], [21]
d
[24,25] [32]
e
[26,27],
[28,29],
[30,31]
CCL3L_PP2 F: TTCTGGACCCACTCCTCACT [12] CCL3L1
R: CTTCTCCACAGCTTCCTAACCA CCL3L3
P: FAM-CTGCCGGCCTCTCT
CCL3L_PP3 F: TGCCTATCTCCGTCTAGAGAGCTT [13] CCL3L1
R: AGAAGGAGGCAGCAGGACACT [33] CCL3L2
P: FAM-TGACTCCAGGCAAGGG-MGB CCL3L3
CCL3L_PP4 F: GGGTATGACTTCTTGAACCGACAAA [1] CCL3L1
R: GGTTCTCTGTTTCTCTATGTGATCCA CCL3L3
P: 6FAM-CATGAAGAGAGCTAAGAGAAC-MGBNFQ
mRNA expression
CCL3L_PP5 F: TCTGCAACCAGGTCCTCTCT [34]
f CCL3L1
R: TTTCTGGACCCACTCCTCAC CCL3L3
CCL3L_PP6 F:AGCCCTGAACAAAGCATCTG [35]
g CCL3L1
R:TGAGAGTTCCCCCTGTCCCCT CCL3L3
Non-Human
F: CCAGTGCTTAACCTTCCTCC
CCL3L_PP7 R: TCAGGCACTCAGCTCCAGGT [11]
P: AGGCCGGCAGGTCTGTGCTGACC
* F = forward primer, R = Reverse primer, P = probe
a SLE;
bRheumatoid arthritis;
cKawasaki disease;
d type 1 diabetes mellitus;
e hepatitis C;
fHuman glioblastoma;
gDendritic cells exposed to contact allergens and irritants
Figure 1 CCL3L gene cluster. Annotation, orientation and mapping of the gene cluster CCL3 (geneID: 6348), CCL3L1 (geneID: 6349), CCL3L2
(geneID: 390788) and CCL3L3 (geneID: 414062) in the chromosome 17 genomic sequence.
Table 2 Identity matrix (%) between the CCL3L-related
genes in complete (5’UTR, exons, introns and 3’UTR)
genomic sequence (bottom left) and b) exonic regions
(top right)
CCL3 CCL3L1 CCL3L2 CCL3L3
CCL3 - 0.957 0.713 0.957
CCL3L1 0.929 - 0.719 1.000
CCL3L2 0.525 0.553 - 0.719
CCL3L3 0.921 0.987 0.560 -
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macaques [11] aligned with the human genomic
sequence as well but were nevertheless specific to both
CCL3L1 and CCL3L3.
Figure 2 illustrates the distribution of CCL3L-related
gene copy number based on the four different assays in
a) Caucasians and b) African-Americans. Based on the
sequence alignment (additional file 1), while CCL3_PP1,
CCL3L_PP2, and CCL3L_PP4 are specific to CCL3L1
and CCL3L2, the assay CCL3_PP3 is specific to all three
genes; CCL3L1, CCL3L2 and CCL3L3. The median gene
copy was 2 for all assays in European Americans; 3 for
CCL3L_PP3 and 4 for CCL3L_P1, CCL3L_P2, and
CCL3L_P4 in African Americans and the means were
2.08, 2.04, 1.84 and 2.13 in European Americans and
3.93, 3.94, 3.3 and 4.04 in African Americans for
CCL3_PP1, CCL3L_PP2, CCL3L_PP3 and CCL3L_PP4,
respectively. Interestingly, CCL3L_PP1 had the lowest
mean in both ethnic groups and CCL3L_PP4 had the
highest mean and median in both ethnic groups. The
concordance rates of gene copy calls were 83%, 64% and
79% between CCL3L_PP1 and CCL3L1_PP2,
CCL3L1_P3, and CCL3L1_P4 assays, respectively in Eur-
opean Americans and 67%, 52%, and 58%, respectively
in African Americans; 68% and 66% between CCL3_PP2
and CCL3_PP3 and CCL3_PP4, respectively in European
Americans and 42% and 58%, respectively in African
Americans and 53% between CCL3_PP3 and CCL3_PP4
in European Americans and 44% in African Americans.
Overall, the concordance rate seems to be relatively
higher in European Americans than African Americans
where the gene copy calls are higher with wider
distributions.
Discussion
The non-specificity of different assays for CCL3L1 gene
copy number raises the question of the gene specificity
reported in earlier studies. Until the genetic architecture
of this complex region is understood, it will be difficult
to evaluate the genes individually and determine if there
is an association between the copy numbers of all the
genes in the cluster or if the association is specific to
the copy number of only one gene [18]. Further, there
m i g h tb es i t u a t i o n si nw h i c hah i g h e rg e n ec o p yo fo n e
gene is detrimental and a higher gene copy of another is
beneficial. Based on existing assays, the distribution of
copy numbers of CCL3L1/CCL3L3 differs in different
ethnic groups, (e.g., median copies of two, four, and six
in Caucasians, Asians, and Africans, respectively)
[12,13]. In our own results, while this seems to be the
case at the population level, there seems to be inconsis-
tencies between the different assays at the individual
level, as shown specifically by the low concordance rates
(Figure 2). Overall, CCL3L_PP4 has a higher mean than
other assays both in African American and European
American could possibly measure all three genes as pre-
viously described [1], but the sequence alignment shows
that the assays are based specific to CCL3L1 and
CCL3L3 and not to the truncated CCL3L2. Neverthe-
less, CCL3L_PP4 is not consistently larger across sam-
ples. On the contrary, CCL3L_PP4 which binds to all
three genes has actually the lowest mean copy number.
This clearly suggests non-specificity of the assays
regardless of the sequence alignment.
If CCL3L1 and CCL3L3 are both diploid in nature
then an individual should possess 4 copies of these
genes based on the assays specific to two of these genes
(Table 1: CCL3L_PP1, CCL3L_PP2, CCL3L_PP4, and
CCL3L_PP5), so it is puzzling why there are several
individuals with 1 or 2 copies, especially among Cauca-
sians as shown in Figure 2. Do they lack one of these
genes completely or do they have one copy of each or
do they have different copy number of each gene? Any
such discrepancy may confound the association from
Figure 2 Gene copy number distribution in Caucasians and African-Americans. Distribution of CCL3L-related gene copy number by four
RT-PCR assays: CCL3L_PP1, CCL3L_PP2, CCL3L_PP3, and CCL3L_PP4 in a) 47 Caucasians and b) 48 African-Americans. The concordance rates
(same gene copy calls) between different assays are shown in the table.
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than the copies of the sequence in the genome. Thus,
further investigation is needed to clarify the distribution
for the sub-fractions of these genes and to understand
how immunity with respect to the affect of each of
these genes has evolved in different populations, includ-
ing non-human primates, who tend to have higher copy
numbers. Theoretically any assay performed to deter-
mine total CCL3L1 and CCL3L3 copies (although does
not distinguish the dose of CCL3L1 and CCL3L3 in
each individual) should reveal the same results and thus
there should be no effect in the association. However, as
we see from our results, the concordance rates are low.
Without a gold-standard it is not possible to reliably
assess which assay is better, but any misclassifications
could lead to incorrect associations. Additionally, there
are several other issues such as dye chemistry, reaction
specificity/conditions and DNA concentrations that
might also affect the assays [19]. Even with exact copy
numbers, while there may not be differences at the
sequence level, there may be differences at the expres-
sion levels and therefore may confound the overall asso-
ciation at the protein level rather than the nucleotide
sequence level. For instance, the affinity of CCL3L1 is
strongest for CCR5 and may be important to know how
many copies of CCL3L1 an individual has versus how
many of total CCL3L1 and CCL3L3.I tr e m a i n st ob e
shown how these two genes are differentially expressed
and also how an expression of one gene might be
affected by differential copy numbers of the others.
They could enhance the affinity, reduce the affinity, or
have no effect. However, while the expression and pro-
tein levels are important, the structural variants of these
genes at the sequence level (copy numbers) needs to be
understood and assayed properly to determine which
ones are functional and what their levels are.
Since the extent of the non-specificity of the current
RT-PCR based assays has not been well defined, the
comparison to delineate the homologous regions pro-
vides basic information for assay development. The
present data show that other genes, such as CCL18 and
CCL24,w h i c hm a yn o tb ei nt h eg e n ec l u s t e r ,a l s o
have overlapping regions (30-34% in CCL18 and 27-
44% in CCL24 with genes in CCL3L cluster). At pre-
sent, different bio-informatics tools are needed to
examine the sequences and to understand their com-
plexities. While our inferences of the RT-PCR based
assays are based on a single reference genome assem-
bly, all previous assays were likely based on the refer-
ence sequence as well and thus our approach provides
a less conservative specificity since polymorphisms
between and within genes in a population could further
confound the specificity of the primers/probes. For
example, although the exonic sequences between
CCL3L1 and CCL3L3 are identical, there is at least one
SNP in the UTR and two in the introns of CCL3L1 and
one in the intron of CCL3L3 (additional file 1) that are
uniquely polymorphic (based on the reference genome)
and can be utilized to develop assays. However, it is yet
to be determined if these are different within genes or
between genes to make a more reliable assay. Addition-
ally, variants between and within copies of the CCL3L-
related genes might influence the function of these
genes. For example, SNPs in CCL3 and CCL3L1 genes
determine their production [20]. Thus, SNPs and copy
numbers are important in examining the production
and expression of these gene levels. Both should be
assayed appropriately.
Recently, as an alternative to RT-PCR, a method for
CCL3L1 copy number determination based on a paralo-
gue ratio test (PRT) has been developed [21]. However,
the primers are non-specific and align with both
CCL3L1 and CCL3L3. With the current methodologies
for determining gene copy numbers, a main assumption
is that the derived gene copy number based on specific
probes represents the whole gene. This may not always
be the case, since only parts of the gene might be dupli-
cated; this may be missed if the probe is not specific for
this segment or may provide a false count when other
segments of the gene are not amplified, especially the
functional segments. In some cases, there might be a
complete gene copy, but subtle differences may be pre-
sent at the sequence level. The orientation of the gene
might be opposite so that expression would not be the
same, or there might be differences in single-nucleotide
polymorphisms (SNPs) between copies. To account for
t h e s ev a r i a b l e s ,c o m p l e t es e q u e n c ed a t ao fa l lc o p i e s
could be required. In summary, we report homology at
t h en u c l e o t i d es e q u e n c el e v el between the different
CCL3L-related gene clusters and primers/probes for the
RT-PCR based assays. The currently used assays for
gene copies of CCL3L1 are evidently non-specific and
thus could overestimate the copy numbers. Based on
the overlapping and non-specific sequences between
these genes, current gene copy assays, such as gene spe-
cific RT-PCR, pyrosequencing, paralogue ratio tests
(PRT), multiplex amplifiable probe hybridization
(MAPH) or multiplex ligation-dependent probe amplifi-
cation (MPLA), could be fine-tuned with broad-range
nested PCR methods to avoid redundant sequences and
other new assays developed. Special precautions, how-
ever, are needed to avoid the homologous sequences.
Non-specificity of the laboratory methods for CNVs
should not be overlooked as we develop different analy-
tical methods to account for heterogeneity in association
results.
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Page 5 of 7Additional file 1: Multiple primer-probe alignment with chemokine
genes. Multiple alignments of the primer-probe pairs used for RT-PCR
based assays in different studies with genomic sequences for four
chemokine genes: CCL3, CCL3L1, CCL3L2 and CCL3L3. The sequences of
the genes were obtained as follows: CCL3 - (34415602 - 34417506),
CCL3L1 - (34623842 - 34625730), CCL3L2 - (34610211 - 34611454), and
CCL3L3 - (34522262 - 34524142) from the genomic sequence of
chromosome 17 sequence (Accession Number NC_000017.10). For each
gene, untranslated region sequences are highlighted in blue, exons in
red, and introns in green. Missing sequences are marked as “-"to
optimize gene alignments. (Differences in the gene sequences are
marked as follows: “*” = CCL3L, “‡” = CCL3L1, “Δ” = CCL3L2, and “†” =
CCL3L3)
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